STAT+: Gilead to test once-a-year HIV prevention shot

Gilead said Tuesday that it will soon begin Phase 3 testing for a drug it believes could prevent HIV infection with just a single shot every year.

Such a medicine, if proven effective, would be the closest thing to a vaccine the HIV field has produced in four decades of research. The company plans to begin the trial next year, with an eye toward regulatory filings in late 2027.

The once-a-year drug is another formulation of lenacapavir, a medicine that already made headlines this year when Gilead published data showing it could prevent HIV infections with just one shot every six months.

Continue to STAT+ to read the full story…